Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on α-CGRP-induced regional haemodynamic changes in anaesthetised rats

Basic and Clinical Pharmacology and Toxicology

Volumn 94, Issue 6, 2004, Pages 291-297

  Arulmani, Udayasankar ^a   Schuijt, Martin P ^a   Heiligers, Jan P C ^a   Willems, Edwin W ^a   Villalón, Carlos M ^b   Saxena, Pramod R ^a,c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; N [2 [[5 AMINO 1 [[4 (4 PYRIDINYL) 1 PIPERAZINYL]CARBONYL]PENTYL]AMINO] 1 [(3,5 DIBROMO 4 HYDROXYPHENYL)METHYL] 2 OXOETHYL] 4 [1,4 DIHYDRO 2 OXO 3(2H) QUINAZOLINYL] 1 PIPERIDINECARBOXAMIDE; OLCEGEPANT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADRENAL BLOOD FLOW; ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN BLOOD FLOW; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; HEART OUTPUT; HEART RATE; INTESTINE BLOOD FLOW; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; MESENTERY BLOOD FLOW; MIGRAINE; MUSCLE BLOOD FLOW; NONHUMAN; PANCREAS BLOOD FLOW; PRIORITY JOURNAL; RAT; SKIN BLOOD FLOW; SPLEEN BLOOD FLOW; SYSTEMIC VASCULAR RESISTANCE;

ANESTHESIA, INTRAVENOUS; ANIMALS; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; CARDIAC OUTPUT; HEART RATE; HEMODYNAMIC PROCESSES; MALE; PIPERAZINES; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; VASODILATION; VASODILATOR AGENTS;

ANIMALIA; SUIDAE;

EID: 3242723103     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto940606.x     Document Type: Article

References (43)

1. Akerman, S., D. J. Williamson, H. Kaube & P. J. Goadsby: Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Brit. J. Pharmacol. 2002, 137, 62-68.
2. Ashina, M., L. Bendtsen, R. Jensen, S. Schifter & J. Olesen: Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 2000, 86, 133-138.
3. Baile, E. M., J. M. Nelems, M. Schulzer & P. D. Pare: Measurement of regional bronchial arterial blood flow and bronchovascular resistance in dogs. J. Appl. Physiol. 1982, 53, 1044-1049.
4. Bell, D. & B. J. McDermott: Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho) physiological significance. Pharmacol. Rev. 1996, 48, 253-288.
5. Bratveit, M., A. Haugan & K. B. Helle: Effects of calcitonin gene-related peptide (CGRP) on regional haemodynamics and on selected hepato-splanchnic arteries from the rat: a comparison with VIP and atriopeptin II. Scand. J. Clin. Lab. Invest. 1991, 51, 167-174.
6. de Hoon, J. N., P. Pickkers, P. Smits, H. A. Struijker-Boudier & L. M. Van Bortel: Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin. Pharmacol. Ther. 2003, 73, 312-321.
7. De Vries, P., C. M. Villalón & P. R. Saxena: Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol. 1999, 375, 61-74.
8. DiPette, D. J., K. Schwarzenberger, N. Kerr & O. B. Holland: Dose-dependent systemic and regional hemodynamic effects of calcitonin gene-related peptide. Amer. J. Med. Sci. 1989, 297, 65-70.
9. Doods, H., G. Hallermayer, D. Wu, M. Entzeroth, K. Rudolf, W. Engel & W. Eberlein: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Brit. J. Pharmacol. 2000, 129, 420-423.
10. Du, X. Y., R. G. Schoemaker, E. Bos & P. R. Saxena: Different pharmacological responses of atrium and ventricle: studies with human cardiac tissue. Eur. J. Pharmacol. 1994, 259, 173-180.
11. Edvinsson, L.: Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 2001, 15, 745-753.
12. Edvinsson, L.: New therapeutic target in primary headaches - blocking the CGRP receptor. Expert Opin. Ther. Targets 2003, 7, 377-383.
13. Edvinsson, L., R. Alm, D. Shaw, R. Z. Rutledge, K. S. Koblan, J. Longmore & S. A. Kane: Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol. 2002, 434, 49-53.
14. Franco-Cereceda, A., C. Gennari, R. Nami, D. Agnusdei, J. Pernow, J. M. Lundberg & J. A. Fischer: Cardiovascular effects of calcitonin gene-related peptides I and II in man. Circ. Res. 1987, 60, 393-397.
15. Gardiner, S. M., A. M. Compton, P. A. Kemp, T Bennett, C. Bose, R. Foulkes & B. Hughes: Antagonistic effect of human alpha-CGRP [8-37] on the in vivo regional haemodynamic actions of human alpha-CGRP. Biochem. Biophys. Res. Commun. 1990, 171, 938-943.
16. Goadsby, P. J. & L. Edvinsson: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993, 33, 48-56.
17. Goadsby, P. J., R. B. Lipton & M. D. Ferrari: Migraine - current understanding and treatment. New Engl. J. Med. 2002, 346, 257-270.
18. Ishikawa, T., N. Okamura, A. Saito & K. Goto: Effects of calcitonin gene-related peptide (CGRP) and isoproterenol on the contractility and adenylate cyclase activity in the rat heart. J. Mol. Cell Cardiol. 1987, 19, 723-727.
19. Kapoor, K., U. Arulmani, J. P. Heiligers, I. M. Garrelds, E. W. Willems, H. Doods, C. M. Villalon & P. R. Saxena: Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Brit. J. Pharmacol. 2003a, 140, 329-338.
20. Kapoor, K., U. Arulmani, J. P. Heiligers, E. W. Willems, H. Doods, C. M. Villalon & P. R. Saxena: Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur. J. Pharmacol. 2003b, 475, 69-77.
21. Ludbrook, J.: Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 1994, 28, 303-311.
22. Maassen VanDenBrink, A., W. A. Bax, N. N. Ramrattan, M. D. Ferrari & P. R. Saxena: Human isolated coronary artery contraction to sumatriptan: a post hoc analysis. Cephalalgia 1999, 19, 651-654.
23. Marshall, I., S. J. Al-Kazwini, P. M. Roberts, N. B. Shepperson, M. Adams & R. K. Craig: Cardiovascular effects of human and rat CGRP compared in the rat and other species. Eur. J. Pharmacol. 1986, 123, 207-216.
24. Moreno, M. J., R. Abounader, E. Hebert, H. Doods & E. Hamel: Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002, 42, 568-576.
25. Okimura, Y., K. Chihara, H. Abe, T. Kita, Y. Kashio, M. Sato & T. Fujita: Calcitonin gene-related peptide-like immunoreactivity in the central nervous system and peripheral organs of rats. Regul. Pept. 1987, 17, 327-337.
26. Olesen, J., H. C. Diener, I. W. Husstedt, P. J. Goadsby, D. Hall, U. Meier, S. Pollentier & L. M. Lesko: Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. New Engl. J. Med. 2004, 350, 1104-1110.
27. Opgaard, O. Saetrum, P. Hasbak, R. de Vries, P. R. Saxena & L. Edvinsson: Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur. J. Pharmacol. 2000, 397, 373-382.
28. Overall, J. E. & R. S. Atlas: Power of univariate and multivariate analyses of repeated measurements in controlled clinical trials. J Clin. Psychol. 1999, 55, 465-485.
29. Overall, J. E. & S. R. Doyle: Implications of chance baseline differences in repeated measurement designs. J. Biopharm. Stat. 1994, 4, 199-216.
30. Overall, J. E. & S. R. Doyle: False-positive error rates in routine application of repeated measurements ANOVA. J. Biopharm. Stat. 1996, 6, 69-81.
31. Poyner, D. R., P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer & S. M. Foord: International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 2002, 54, 233-246.
32. Rasmussen, T. N., P. Schmidt, S. S. Poulsen & J. J. Holst: Localisation and neural control of the release of calcitonin gene- related peptide (CGRP) from the isolated perfused porcine ileum. Regul. Pept. 2001, 98, 137-143.
33. Saxena, P. R.: Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Experimental headache models. Eds.: J. Olesen and M. A. Moskowitz. Lippincott-Raven Publishers, Philadelphia, USA, 1995, pp. 189-198.
34. Saxena, P. R., H. C. Schamhardt, R. P. Forsyth & J. Hoeve: Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput. Programs Biomed 1980, 12, 63-84.
35. 1B/1D receptor agonists in the acute treatment of migraine. In: The headaches. Eds.: J. Olesen, P. Tfelt-Hansen and K. M. A. Welch. Lippincott Williams & Wilkins, Philadelphia, USA, 2000, pp. 411-438.
36. Schuijt, M. P., R. de Vries, P. R. Saxena & A. H. Danser: No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats. J. Hypertens. 1999, 17, 1879-1884.
37. Sternini, C., R. De Giorgio & J. B. Furness: Calcitonin gene-related peptide neurons innervating the canine digestive system. Regul. Pept. 1992, 42, 15-26.
38. Van Gelderen, E. M., X. Y. Du, R. G. Schoemaker & P. R. Saxena: Carotid blood flow distribution, haemodynamics and inotropic responses following calcitonin gene-related peptide in the pig. Eur. J. Pharmacol. 1995, 284, 51-60.
39. van Rossum, D., U. K. Hanisch & R. Quirion: Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci. Biobehav. Rev. 1997, 21, 649-678.
40. Ventura, S., W. A. Lau, S. Buljubasich & J. N. Pennefather: Calcitonin gene-related peptide (CGRP) inhibits contractions of the prostatic stroma of the rat but not the guinea-pig. Regul. Pept. 2000, 91, 63-73.
41. 8-37. Brit. J. Pharmacol. 2002, 136, 120-126.
42. Williamson, D. J. & R. J. Hargreaves: Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 2001, 53, 167-178.
43. Wimalawansa, S. J.: Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr. Rev. 1996, 17, 533-585.